New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

BioAge Labs, Inc.

Contributing Author

Recent Articles by BioAge Labs, Inc.

Jan-21	BioAge Announces Pricing of Upsized $115.0 Million Public Offering BIOA GlobeNewswire
Jan-20	BioAge Announces Proposed Public Offering BIOA GlobeNewswire
Jan-20	BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 BIOA GlobeNewswire
Jan-12	BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk BIOA GlobeNewswire
Dec-04	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA GlobeNewswire
Nov-25	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference BIOA GlobeNewswire
Nov-07	BioAge Labs to Present at Jefferies Global Healthcare Conference in London BIOA GlobeNewswire
Nov-06	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Aug-20	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
Aug-15	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA GlobeNewswire
Aug-06	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Jun-21	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions BIOA GlobeNewswire
Jun-17	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank BIOA GlobeNewswire
Jun-03	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates BIOA GlobeNewswire
May-29	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic BIOA GlobeNewswire
May-27	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
May-06	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.